A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT06820463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer
Study identification
- NCT ID
- NCT06820463
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 390 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- Fluorouracil Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Panitumumab Drug
- Telisotuzumab Adizutecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2025
- Primary completion
- Feb 29, 2028
- Completion
- Mar 31, 2028
- Last update posted
- Apr 14, 2026
2025 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center /ID# 270255 | Duarte | California | 91010 | Recruiting |
| Yale New Haven Hospital /ID# 270565 | New Haven | Connecticut | 06510 | Recruiting |
| Hope And Healing Cancer Services /ID# 271562 | Hinsdale | Illinois | 60521 | Recruiting |
| Dana-Farber Cancer Institute /ID# 270624 | Boston | Massachusetts | 02215 | Recruiting |
| Saint Lukes Hospital of Kansas City /ID# 270633 | Kansas City | Missouri | 64111 | Recruiting |
| Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646 | Omaha | Nebraska | 68130 | Recruiting |
| University of North Carolina Medical Center /ID# 267786 | Chapel Hill | North Carolina | 27514 | Recruiting |
| Oncology Hematology Care - Eastgate /ID# 271493 | Cincinnati | Ohio | 45245 | Recruiting |
| Texas Oncology - Austin Midtown /ID# 271354 | Austin | Texas | 78705 | Recruiting |
| Texas Oncology - Deke Slayton Cancer Center /ID# 271355 | Webster | Texas | 77598 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06820463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06820463 live on ClinicalTrials.gov.